Multiple sclerosis immunopathic trait and HLA-DR(2)15 as independent risk factors in multiple sclerosis

Multiple Sclerosis

Volumn 13, Issue 4, 2007, Pages 441-445

  Callander, Margarita ^a   Haghighi, S ^b   Landtblom, A M ^a   Ahlgren, C E ^b   Nilsson, S I ^c   Rydberg, L ^b   Al Khoury, H ^a   Rosegren, L ^b   Andersen, O ^d  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Genetic susceptibility; HLA; Multiple sclerosis; Multiple sclerosis trait

Indexed keywords

HLA ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR10 ANTIGEN; HLA DR103 ANTIGEN; HLA DR11 ANTIGEN; HLA DR12 ANTIGEN; HLA DR13 ANTIGEN; HLA DR14 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; HLA DR6 ANTIGEN; HLA DR7 ANTIGEN; HLA DR8 ANTIGEN; HLA DR9 ANTIGEN; IMMUNOGLOBULIN G; OLIGOCLONAL BAND; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOBLOTTING; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; REFERENCE VALUE; RISK ASSESSMENT; SIBLING; STATISTICAL SIGNIFICANCE;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; REFERENCE VALUES; RISK FACTORS; SIBLINGS;

EID: 34249001261     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070264     Document Type: Article

References (25)

1. Sadovnick A, Ebers G, Dyment D, Risch N. Evidence for the genetic basis of multiple sclerosis. The Canadian Collaborative Group. Lancet 1996; 347: 1728-30.
2. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994; 36: 189-93.
3. Duquette P, Charest L. Cerebrospinal fluid findings in healthy siblings of multiple sclerosis patients. Neurology 1986; 36: 727-29.
4. Poser CM. The pathogenesis of multiple sclerosis: a critical reappraisal. Acta Neuropathol 1986; 71: 1-10.
5. Poser CM. The pathogenesis of multiple sclerosis. Additional considerations. J Neurol Sci 1993; 115: S3-S15.
6. Poser CM. The multiple sclerosis trait: the premorbid stage of multiple sclerosis. A hypothesis. Acta Neurol Scand 2004; 109: 239-43.
7. Sadovnick AD. The multiple sclerosis trait. A disease waiting to happen? Clin Neurol Neurosurg 2004; 106: 172-74.
8. Haghighi S, Andersen O, Rosengren L, Bergström T, Wahlström J, Nilsson S. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls. J Neurol 2000; 247: 616-22.
9. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38: 1-15.
10. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221-25.
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines and research protocols. Ann Neurol 1983; 13: 227-31.
12. Crowe J, Feuser P, Goergen B. Rapid nucleic acid purification for reliable PCR. J NIH Res 1993; 39: 73.
13. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 223-35.
14. Barcellos LF, Oksenberg JR, Begovich AB et al.; Multiple Sclerosis Genetics Group. HLA-DR(2)15 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710-16.
15. Weatherby SJ, Thomson W, Pepper L, Martin ER, Scmidt S, Vittighoff E et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 2001; 248: 304-10.
16. Nuwer MR, Visscher BR, Packwood JW, Donn R, Worthington J, Mann CL et al. Evoked potential testing in relatives of multiple sclerosis patients. Ann Neurol 1985; 18: 30-34.
17. Siger-Zajdel M, Filippi M, Selmaj K, Namerow NS. MTR discloses subtle changes in the normal appearing tissue from relatives of patient with MS. Neurology 2002; 58: 317-20.
18. Jagodic M, Marta M, Becanovic K, Sheung JR, Nohra R, Olsson T et al. Resolution of a 16.8-Mb autoimmunity-regulating rat chromosome 4 region into multiple encephalomyelitis quantitative trait loci and evidence for epistasis. J Immunol 2005; 174: 918-24.
19. Baranzini SE, Oksenberg JR, Hauser SL. New in-sights into the genetics of multiple sclerosis. J Rehabil Res Dev 2002; 39: 201-10.
20. Haines JL, Terwedow EIA, Burgess K, Pericak-Vance MA, Rimmler JB, Martin ER et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 1998; 7: 1229-34.
21. Sawcer SJ, Meranian M, Setakis E, Curwen V, Akesson E, Hensiek A et al. A whole genome screen for linkage disequilibrium. in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002; 125: 1337-47.
22. Fukazawa T, Kikuchi S, Sasaki H, Hamada K, Hamada T, Miyasaka K et al. The significance of oligoclonal bands in multiple sclerosis in Japan: relevance of immunogenetic backgrounds. J Neurol Sci 1998; 158: 209-14.
23. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006; 67: 1062-64.
24. Jagodic M, Becanovic K, Sheng JR, Wu X, Bäck-dahl L, Lorentzen J et al. An advanced intercross line resolves Eae18 into two narrow quantitative loci syntenic to multiple sclerosis candidate loci. J Immunol 2004; 173: 1366-73.
25. Gay D, Esiri M. Blood-brain damage in acute MS plaques. Brain 1991; 114: 557-72.